Impact of adalimumab in patients with active noninfectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study
Background/aim: This study evaluated real-life adalimumab impact in patients with active non-infectious intermediate, posterior, or panuveitis (NIIPPU).
Methods: Adults with active NIIPPU received adalimumab in this prospective, observational study (06/2017-04/2020). Patients were evaluated at baseline (V0) and four follow-up visits over 12 months (V1-V4).
Primary endpoint: proportion of patients achieving quiescence (anterior chamber (AC) cells grade and vitreous haze (VH) grade≤0.5+ in both eyes, no new active chorioretinal lesions) at any follow-up visit. Secondary endpoints: proportion of patients achieving quiescence at each visit; proportion of patients maintaining response; and proportion of patients with flares. Workability, visual function, healthcare resource utilisation, and safety were evaluated.
Results: Full analysis set included 149 patients. Quiescence at any follow-up visit was achieved by 129/141 (91%) patients. Quiescence at individual visits was achieved by 99/145 (68%), 110/142 (77%), 102/131 (78%), and 99/128 (77%) patients at V1-V4, respectively. Number of patients in corticosteroid-free quiescence increased from 51/147 (35%; V1) to 67/128 (52%; V4; p<0.05). Proportion of patients with maintained response increased from 89/141 (63%; V2) to 92/121 (76%; V4; p<0.05) and proportion of patients with flare decreased from 25/145 (17%; V1) to 13/128 (10%; V4; p=0.092). Workability and visual function improved throughout the study. Proportion of patients with medical visits for uveitis decreased from 132/149 (89%; V0) to 27/127 (21%; V4). No new safety signals were observed.
Conclusion: These results demonstrated adalimumab effectiveness in improving quality of life while reducing economic burden of active NIIPPU.
Funding
AbbVie
History
Data Availability Statement
Data are available upon reasonable requestComments
The original article is available at https://bjo.bmj.com/Published Citation
Pleyer U. et al. Impact of adalimumab in patients with active non-infectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study. Br J Ophthalmol. 2023;107(12):1892-1899.Publication Date
19 October 2022External DOI
PubMed ID
36261259Department/Unit
- Ophthalmology
- School of Pharmacy and Biomolecular Sciences
Research Area
- Health Professions Education
- Chemistry and Pharmaceutical Sciences
- Biomaterials and Regenerative Medicine
- Surgical Science and Practice
- Immunity, Infection and Inflammation
Publisher
BMJ Pub. GroupVersion
- Published Version (Version of Record)